Director Jeffrey Stein Buys $1.65M in IDEAYA Biosciences Shares
Summary
IDEAYA Biosciences Director Jeffrey Stein acquired 50,000 shares of common stock for approximately $1.65 million on March 2, 2026. This substantial personal investment by a director signals strong confidence in the company's future prospects. This purchase follows the company's recent announcement of robust Q4 and full-year 2025 financial results, including a significant cash position of $1.05 billion. Traders will likely view this insider buying as a positive indicator, reinforcing the bullish sentiment established by the recent earnings report. Investors will watch for continued operational execution and pipeline progress.
At the time of this announcement, IDYA was trading at $33.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $13.45 to $39.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.